68Ga-P15-041, A Novel Bone Imaging Agent for Diagnosis of Bone Metastases

Objectives68Ga-P15-041 (68Ga-HBED-CC-BP) is a novel bone-seeking PET radiotracer, which can be readily prepared by using a simple kit formulation and an in-house 68Ga/68Ge generator. The aim of this study is to assess the potential human application of 68Ga-P15-041 for clinical PET/CT imaging and to...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Rui Guo, Xiangxi Meng, Fei Wang, Jiangyuan Yu, Qing Xie, Wei Zhao, Lin Zhu, Hank F. Kung, Zhi Yang, Nan Li
Formato:	article
Lenguaje:	EN
Publicado:	Frontiers Media S.A. 2021
Materias:	PET/CT bisphosphonate cancer bone metastases SUV and Gallium-68 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/d5d9d4b18ae24db89d5f0e7688d24e3f
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d5d9d4b18ae24db89d5f0e7688d24e3f
record_format	dspace
spelling	oai:doaj.org-article:d5d9d4b18ae24db89d5f0e7688d24e3f2021-11-30T20:50:43Z68Ga-P15-041, A Novel Bone Imaging Agent for Diagnosis of Bone Metastases2234-943X10.3389/fonc.2021.766851https://doaj.org/article/d5d9d4b18ae24db89d5f0e7688d24e3f2021-11-01T00:00:00Zhttps://www.frontiersin.org/articles/10.3389/fonc.2021.766851/fullhttps://doaj.org/toc/2234-943XObjectives68Ga-P15-041 (68Ga-HBED-CC-BP) is a novel bone-seeking PET radiotracer, which can be readily prepared by using a simple kit formulation and an in-house 68Ga/68Ge generator. The aim of this study is to assess the potential human application of 68Ga-P15-041 for clinical PET/CT imaging and to compare its efficacy to detect bone metastases of different cancers with 99mTc-MDP whole-body bone scintigraphy (WBBS).MethodsInitial kinetic study using Patlak analysis and parametric maps were performed in five histopathologically proven cancer patients (three males, two females) using 68Ga-P15-041 PET/CT scan only. Another group of 51 histopathologically proven cancer patients (22 males, 29 females) underwent both 99mTc-MDP WBBS and 68Ga-P15-041 PET/CT scans within a week, sequentially. Using either pathology examination or follow-up CT or MRI scans as the gold standard, the diagnostic efficacy and receiver operating characteristic curve (ROC) of the two methods in identifying bone metastases were compared (p <0.05, statistically significant).ResultsFifty-one patients were imaged, and 174 bone metastatic sites were identified. 68Ga-P15-041 PET/CT and 99mTc-MDP WBBS detected 162 and 81 metastases, respectively. Sensitivity, specificity, positive predictive value, negative predictive value and accuracy of 68Ga-P15-041 PET/CT and 99mTc-MDP WBBS were 93.1% vs 81.8%, 89.8% vs 90.7%, 77.5% vs 69.2%, 97.2% vs 93.4% and 90.7% vs 88.4%, respectively. Our results showed that the mean of SUVmax was significantly higher in metastases than that in benign lesions, 15.1 ± 6.9 vs. 5.6 ± 1.3 (P <0.001). Using SUVmax = 7.6 as the cut-off value by PET/CT, it was possible to predict the occurrence of metastases (AUC = 0.976; P <0.001; 95% CI: 0.946–0.999). However, it was impossible to distinguish osteoblastic bone metastases from osteolytic bone lesions. Parametric maps based on Patlak analysis provided excellent images and highly valuable quantitative information.Conclusions68Ga-P15-041 PET/CT, offering a rapid bone scan and high contrast images in minutes, is superior to the current method of choice in detecting bone metastases. It is reasonable to suggest that 68Ga-P15-041 PET/CT could become a valuable routine nuclear medicine procedure in providing excellent images for detecting bone metastases in cancer patients. 68Ga-P15-041 could become a valuable addition expanding the collection of 68Ga-based routine nuclear medicine procedures where 18F fluoride is not currently available.Rui GuoXiangxi MengFei WangJiangyuan YuQing XieWei ZhaoLin ZhuHank F. KungZhi YangNan LiFrontiers Media S.A.articlePET/CTbisphosphonatecancerbone metastasesSUV and Gallium-68Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENFrontiers in Oncology, Vol 11 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	PET/CT bisphosphonate cancer bone metastases SUV and Gallium-68 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	PET/CT bisphosphonate cancer bone metastases SUV and Gallium-68 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Rui Guo Xiangxi Meng Fei Wang Jiangyuan Yu Qing Xie Wei Zhao Lin Zhu Hank F. Kung Zhi Yang Nan Li 68Ga-P15-041, A Novel Bone Imaging Agent for Diagnosis of Bone Metastases
description	Objectives68Ga-P15-041 (68Ga-HBED-CC-BP) is a novel bone-seeking PET radiotracer, which can be readily prepared by using a simple kit formulation and an in-house 68Ga/68Ge generator. The aim of this study is to assess the potential human application of 68Ga-P15-041 for clinical PET/CT imaging and to compare its efficacy to detect bone metastases of different cancers with 99mTc-MDP whole-body bone scintigraphy (WBBS).MethodsInitial kinetic study using Patlak analysis and parametric maps were performed in five histopathologically proven cancer patients (three males, two females) using 68Ga-P15-041 PET/CT scan only. Another group of 51 histopathologically proven cancer patients (22 males, 29 females) underwent both 99mTc-MDP WBBS and 68Ga-P15-041 PET/CT scans within a week, sequentially. Using either pathology examination or follow-up CT or MRI scans as the gold standard, the diagnostic efficacy and receiver operating characteristic curve (ROC) of the two methods in identifying bone metastases were compared (p <0.05, statistically significant).ResultsFifty-one patients were imaged, and 174 bone metastatic sites were identified. 68Ga-P15-041 PET/CT and 99mTc-MDP WBBS detected 162 and 81 metastases, respectively. Sensitivity, specificity, positive predictive value, negative predictive value and accuracy of 68Ga-P15-041 PET/CT and 99mTc-MDP WBBS were 93.1% vs 81.8%, 89.8% vs 90.7%, 77.5% vs 69.2%, 97.2% vs 93.4% and 90.7% vs 88.4%, respectively. Our results showed that the mean of SUVmax was significantly higher in metastases than that in benign lesions, 15.1 ± 6.9 vs. 5.6 ± 1.3 (P <0.001). Using SUVmax = 7.6 as the cut-off value by PET/CT, it was possible to predict the occurrence of metastases (AUC = 0.976; P <0.001; 95% CI: 0.946–0.999). However, it was impossible to distinguish osteoblastic bone metastases from osteolytic bone lesions. Parametric maps based on Patlak analysis provided excellent images and highly valuable quantitative information.Conclusions68Ga-P15-041 PET/CT, offering a rapid bone scan and high contrast images in minutes, is superior to the current method of choice in detecting bone metastases. It is reasonable to suggest that 68Ga-P15-041 PET/CT could become a valuable routine nuclear medicine procedure in providing excellent images for detecting bone metastases in cancer patients. 68Ga-P15-041 could become a valuable addition expanding the collection of 68Ga-based routine nuclear medicine procedures where 18F fluoride is not currently available.
format	article
author	Rui Guo Xiangxi Meng Fei Wang Jiangyuan Yu Qing Xie Wei Zhao Lin Zhu Hank F. Kung Zhi Yang Nan Li
author_facet	Rui Guo Xiangxi Meng Fei Wang Jiangyuan Yu Qing Xie Wei Zhao Lin Zhu Hank F. Kung Zhi Yang Nan Li
author_sort	Rui Guo
title	68Ga-P15-041, A Novel Bone Imaging Agent for Diagnosis of Bone Metastases
title_short	68Ga-P15-041, A Novel Bone Imaging Agent for Diagnosis of Bone Metastases
title_full	68Ga-P15-041, A Novel Bone Imaging Agent for Diagnosis of Bone Metastases
title_fullStr	68Ga-P15-041, A Novel Bone Imaging Agent for Diagnosis of Bone Metastases
title_full_unstemmed	68Ga-P15-041, A Novel Bone Imaging Agent for Diagnosis of Bone Metastases
title_sort	68ga-p15-041, a novel bone imaging agent for diagnosis of bone metastases
publisher	Frontiers Media S.A.
publishDate	2021
url	https://doaj.org/article/d5d9d4b18ae24db89d5f0e7688d24e3f
work_keys_str_mv	AT ruiguo 68gap15041anovelboneimagingagentfordiagnosisofbonemetastases AT xiangximeng 68gap15041anovelboneimagingagentfordiagnosisofbonemetastases AT feiwang 68gap15041anovelboneimagingagentfordiagnosisofbonemetastases AT jiangyuanyu 68gap15041anovelboneimagingagentfordiagnosisofbonemetastases AT qingxie 68gap15041anovelboneimagingagentfordiagnosisofbonemetastases AT weizhao 68gap15041anovelboneimagingagentfordiagnosisofbonemetastases AT linzhu 68gap15041anovelboneimagingagentfordiagnosisofbonemetastases AT hankfkung 68gap15041anovelboneimagingagentfordiagnosisofbonemetastases AT zhiyang 68gap15041anovelboneimagingagentfordiagnosisofbonemetastases AT nanli 68gap15041anovelboneimagingagentfordiagnosisofbonemetastases
_version_	1718406292047921152

68Ga-P15-041, A Novel Bone Imaging Agent for Diagnosis of Bone Metastases

Ejemplares similares